Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsUnger, Wendy Wj
Mayer, Christian T
van Kooyk, Yvette
MetadataShow full item record
AbstractTherapeutic vaccinations against cancer are still largely ineffective. Major caveats are inefficient delivery of tumor antigens to dendritic cells (DCs) and excessive immune suppression by Foxp3(+) regulatory T cells (Tregs), resulting in defective T cell priming and failure to induce tumor regression. To circumvent these problems we evaluated a novel combinatorial therapeutic strategy. We show that tumor antigen targeting to DC-SIGN in humanized hSIGN mice via glycans or specific antibodies induces superior T cell priming. Next, this targeted therapy was combined with transient Foxp3(+) Treg depletion employing hSIGNxDEREG mice. While Treg depletion alone slightly delayed B16-OVA melanoma growth, only the combination therapy instigated long-term tumor regression in a substantial fraction of mice. This novel strategy resulted in optimal generation of antigen-specific activated CD8(+) T cells which accumulated in regressing tumors. Notably, Treg depletion also allowed the local appearance of effector T cells specific for endogenous B16 antigens. This indicates that antitumor immune responses can be broadened by therapies aimed at controlling Tregs in tumor environments. Thus, transient inhibition of Treg-mediated immune suppression potentiates DC targeted antigen vaccination and tumor-specific immunity.
CitationAntigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression. 2015, 4 (8):e970462 Oncoimmunology
AffiliationInstitute of Experimental Virology, Twincore, Centre for Experimental and Clinical Infection Research, Hannover, Germany.
The following license files are associated with this item:
- Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
- Authors: Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, Smyth MJ, Hamann A, Huehn J, Sparwasser T
- Issue date: 2010 Oct 15
- Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
- Authors: Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F
- Issue date: 2004 Nov
- In vivo targeting of human DC-SIGN drastically enhances CD8⁺ T-cell-mediated protective immunity.
- Authors: Hesse C, Ginter W, Förg T, Mayer CT, Baru AM, Arnold-Schrauf C, Unger WW, Kalay H, van Kooyk Y, Berod L, Sparwasser T
- Issue date: 2013 Oct
- β-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8⁺ T cells.
- Authors: Liang X, Fu C, Cui W, Ober-Blöbaum JL, Zahner SP, Shrikant PA, Clausen BE, Flavell RA, Mellman I, Jiang A
- Issue date: 2014 Jan
- Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity.
- Authors: Yi H, Guo C, Yu X, Gao P, Qian J, Zuo D, Manjili MH, Fisher PB, Subjeck JR, Wang XY
- Issue date: 2011 Nov 1